Harbourvest Partners LLC Aligos Therapeutics, Inc. Transaction History
Harbourvest Partners LLC
- $184 Million
- Q2 2024
A detailed history of Harbourvest Partners LLC transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Harbourvest Partners LLC holds 18,783 shares of ALGS stock, worth $154,020. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,783
Previous 18,783
-0.0%
Holding current value
$154,020
Previous $18,000
66.67%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding ALGS
# of Institutions
52Shares Held
47.3MCall Options Held
1.4KPut Options Held
300-
Armistice Capital, LLC New York, NY7.26MShares$59.5 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$52.4 Million0.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$50 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5MShares$41 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$29.1 Million0.18% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $326M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...